Inhaled NAC in Treatment of IPF
Reason given: The study encountered challenges during startup due to the COVID-19 epidemic and was withdrawn.
Key facts
- Where
- Aurora, United StatesSee the site
- Phase
- Phase 1/2
Where in United States
- University of Colorado Anschutz Medical CampusAurora, United StatesNo longer taking part
Trial details
- Who runs it
- University of Colorado, Denver
- Trial code
- NCT03720483
- Record updated
- 8 June 2021
- Original description
This study plans to learn more about the safety and tolerability of inhaled N-Acetylcysteine (NAC) in patients with pulmonary fibrosis. The study will also create a bank of data, blood, and sputum from IPF patients for future research.Read full original descriptionShow less
Pilot Study to Evaluate Inhaled N-Acetylcysteine in Pulmonary Fibrosis
This study plans to learn more about the safety and tolerability of inhaled N-Acetylcysteine (NAC) in patients with pulmonary fibrosis. The study will also create a bank of data, blood, and sputum from IPF patients for future research.
Inclusion: Diagnosed by study team with expertise in IPF utilizing standard ATS/ERS definition of "probable" or "definite" IPF; DLCO >50% predicted; FVC >60% predicted; FEV1/FVC > 0.7.
Exclusion: Currently using NAC, hypertonic saline, or DNase (dornase alfa) inhalation therapy; History of bronchospasm (requiring treatment); Current acute exacerbation of their IPF disease; History of asthma, COPD, coronary artery disease, or cancer; Current smoker; Supplemental O2 requirement > 4 liters/min via nasal cannula.